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Abstract: Heart failure is increasing in prevalence, with approximately 26 million patients affected
worldwide. This represents a significant cause of morbidity and mortality. Statistics regarding heart failure
patient age, hospitalization likelihood, and mortality differ significantly by country. Heart failure patients
are typically classified by ejection fraction, with distinct phenotypes associated with reduced ejection
fraction (rEF) or preserved ejection fraction (pEF). Heart failure has a significant financial impact related to
hospitalization, medication, and procedural expenses. The costs of heart failure also extend to the reduced
quality of life conferred by heart failure symptoms. Management of heart failure includes a variety of
interventions, including mechanical circulatory support (MCS). MCS, including left ventricular assist devices
(LVADs), right ventricular assist devices (RVADs) and extracorporeal membrane oxygenation (ECMO),
has been a means of managing end stage heart failure. Given the relative scarcity of transplant organs, the
utilization of MCS, particularly as a bridge to transplantation (BTT) has grown significantly. In this review,
we discuss statistics related to heart failure and MCS. We evaluate how patients are classified and examine
global trends and regional differences. We then address MCS therapies, the costs associated with heart
failure, the impact of heart failure on patient quality of life, and data regarding morbidity and mortality.
Keywords: Heart failure; prevalence; statistics; mechanical circulatory support (MCS); left ventricular assist device
(LVAD)
Submitted Jan 31, 2020. Accepted for publication May 13, 2020.
doi: 10.21037/atm-20-1127
View this article at: http://dx.doi.org/10.21037/atm-20-1127

Introduction
Heart failure continues to plague the world; an estimated
26 million people have heart failure (1). Of the deaths
attributed to cardiovascular disease in 2016, approximately
300,000 were estimated to be due to heart failure. Heart
failure has been considered a pandemic, but primarily
due to increasing prevalence (more people living with the
disease), as opposed to increased incidence (more people
diagnosed with the disease). In the United Kingdom (UK),
prevalence increased 23% between 2002 and 2014. This
increase in prevalence has been largely attributed to the
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improvements in medical management. In the United
States of America (USA), 85.6 million adults have at least
one type of cardiovascular disease, and it is estimated that
1–3% of adults (over 6.2 million) were living with heart
failure in 2016 (2), with prevalence increasing with age. By
2030, this number is predicted to increase to more than
8 million (3). Worldwide prevalence is similarly estimated to
be between 1–3% in developed nations, with prevalence by
country shown in Figure 1. After people are diagnosed with
heart failure, the mortality risk is high—50% die within
5 years, and 90% die within 10 years. When limited to an
older population, utilizing the USA Medicare database,
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Figure 1 Age-standardized global prevalence rates of cardiomyopathy and myocarditis per 100,000, both sexes, 2017. Global Burden of
Disease Study 2017. Global Burden of Disease Study 2017 (GBD 2017) Results. Seattle: Institute for Health Metrics and Evaluation (IHME),
2018. Available online: http://vizhub.healthdata.org/gbd-compare/

there is 37% mortality within 1 year, suggesting increased
mortality in an older subgroup, although this may simply
represent lead time bias and/or reflect unique aspects of the
USA healthcare system (4).
Global trends
There is a growing body of research that attempts
to evaluate the regional differences in heart failure
presentation and treatment. One of the major challenges to
more broadly evaluating heart failure has been a lack of data
from developing nations, but recent studies have attempted
to compare the heart failure patient populations in Asia
and sub-Saharan Africa to Europe and North America.
Compared to patients in Europe and North America,
patients in Asia tended to be younger (55 vs. 67 years
mean), had fewer comorbidities [including chronic
obstructive pulmonary disease (COPD), despite increased
smoking rates], and had less restricted functional status (5).
There also tended to be different etiologies—post infectious
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cardiomyopathies, including rheumatic heart disease, were
more common in developing nations (although decreasing
in incidence relative to non-infectious etiologies, such
as hypertensive or ischemic cardiomyopathies) (6), while
ischemic heart disease was predominant in Europe and
North America. Heart failure patients in Asia, however, had
higher rates of mortality and hospitalization. Within Asian
countries, however, there are significant differences. Japan
and South Korea had significantly lower mortality rates
than that seen in Europe and North America, and India and
the Philippines had significantly lower hospitalization rates
European and North American heart failure patients (7).
In sub-Saharan Africa, hypertensive heart disease was
similarly common, with a pooled prevalence of 39.2%.
Cardiomyopathy had a prevalence of 22.7%, rheumatic
heart disease had 13.8%, and ischemic heart disease had
a 7.2% prevalence. Right heart failure and pericardial
disease were less common etiologies, with pulmonary
tuberculosis and HIV as the leading causes, respectively.
A high readmission rate (34.9%) was also noted (6). The
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USA has noticed a downward trend in hospital admissions
for heart failure, although readmission rates have increased
(16.5% any-cause) (8) for those patients who have an
initial hospitalization. Rather than readmission for heart
failure itself, however, comorbidities tend to drive the
hospitalization (4).
Patient characteristics
Patients with heart failure are categorized as either
having preserved ejection fraction (pEF), defined by a
left ventricular ejection fraction greater than 50% or
reduced ejection fraction (rEF) defined by an ejection
fraction less than 40%—these subcategories tend to differ
phenotypically. Patients with pEF are more often older,
female, and have higher rates of atrial fibrillation and
hypertension. Patients with rEF are more commonly male
and have a history of myocardial infarction (9). There is
some thought to separate out patients with mid-range
ejection fraction as well, as they tend to phenotypically
mix symptoms that patients with preserved and rEF
demonstrate. These patients with mid-range ejection
fraction fall into one of three categories-patients who have
improved ejection fraction (who were previously HFrEF),
patients who have worsened ejection fraction (who were
previously HFpEF), or patients who have consistent ejection
fractions in the 40–50% range. Ninety percent of patients
who fell into this mid-range category are either improved
or worsened ejection fraction; only 10% were stably in the
40–50% range. There have not been significant mortality
differences noted between the groups, or at least, there have
been inconsistencies across the literature (10).
There have been multiple attempts made to further sort
patients beyond their ejection fraction. One study sorted
patients with HFpEF into three phenotypic categories:
young people with moderate diastolic dysfunction and
normal brain natriuretic peptide levels, obese patients
with diabetes, obstructive sleep apnea (OSA), and severely
reduced left ventricular relaxation, and older patients with
chronic kidney disease, pulmonary hypertension, and right
ventricular dysfunction. Others have more simply classified
patients with HFpEF by the presence or absence of specific
comorbidities (2).
A recent study evaluated patient presentation and
characteristics on a global scale, REPORT-HF. It found that
patients commonly presented due to ischemia in Southeast
Asia (25.6%), the Western Pacific (17.1%), the Middle East
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and Africa (16.2%). Hypertension, type 2 diabetes, and
chronic kidney disease were common universally (63.6%,
36.7%, and 20.3% respectively). Patients in Southeast
Asia, Africa and the Middle East were noted to have worse
baseline functional status [New York Heart Association
(NYHA) class], while patients in Europe were noted to
be much more likely to have atrial arrhythmia histories
compared to patients in Southeast Asia (45.7% vs. 8.2%).
COPD was a more common comorbidity in North America
than elsewhere (27% vs. 19%) (5).
Mechanical circulatory support (MCS) in heart
failure
MCS may be offered to patients with advanced heart
failure. Multiple different registries and collectives have
been created to share data about patients receiving MCS.
The Interagency Registry for Mechanically Assisted
Circulatory Support (INTERMACS) was established
in 2005. INTERMACS joined the Society of Thoracic
Surgeons (STS) National Database as one of its components
on January 1, 2018 (11). Additional databases include the
European Registry for Patients with Mechanical Circulatory
Support (EUROMACS) of the European Association for
Cardio-Thoracic Surgery (EACTS) (12), the Japanese
registry for Mechanically Assisted Circulatory Support
(J-MACS) (13), and the UK Registry. The International
Society for Heart and Lung Transplantation (ISHLT)
Mechanically Assisted Circulatory Support (IMACS) has
collected data since it originated in 2013. It currently
collects data from STS-INTERMACS, EUROMACS,
J-MACS, UK Registry, and 24 additional hospitals. The
3rd IMACS report, with data through December 31, 2017,
indicated it had collected data from over 16,000 patients
from across the world (14). Data from these registries
provide robust information on the MCS patient population.
Additionally, long-term follow-up from prospective
large trials such as MagLev Technology in Patients
Undergoing Mechanical Circulatory Support Therapy
with HeartMate 3 (MOMENTUM 3) (15) and Registry
to Evaluate the HeartWare Left Ventricular Assist System
(ReVOLVE) also provide valuable data (16). In addition
to MCS, patients with heart failure may be candidates
for heart transplantation. A Registry for Thoracic Organ
Transplantation documents recipients of heart and heartlung transplants and is maintained by ISHLT, with over
131,000 adult heart transplant recipients through June
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Table 1 INTERMACS profile descriptions (14)
INTERMACS profile

Description

LVAD implantation percentage 2013-17

1

Critical cardiogenic shock

17%

2

Progressive decline, despite intravenous inotropic support

33%

3

Stable on intravenous inotropic support

34%

4

Resting symptoms on oral therapy

13%

5

Exertion intolerant, comfortable at rest, but no activity

2%

6

Exertion limited

1%

7

Advanced New York Heart Association (NYHA) III symptoms

1%

INTERMACS, the Interagency Registry for Mechanically Assisted Circulatory Support; LVAD, left ventricular assist device.

2018. It is one of the most robust of the aforementioned
databases (17).
First generation left ventricular assist devices (LVADs)
were refined in the 1990s (HeartMate I, HeartMateVE, and
HeartMate XVE) and were pulsatile volume displacement
pumps which generated forward flow. Second generation
LVADs (HeartMate-II) were continuous flow, rotary pumps.
They used continuous axial flow to pull blood through
the pump and generate forward flow. These devices were
smaller and had fewer moving parts. The third generation
LVADs (HeartMate-III and HeartWare VAD) used
centrifugal pumps with a spinning impeller to propel blood
and produce blood flow (18). As pumps continue to become
more advanced, ongoing controversy persists regarding the
appropriate time to implant the devices (11,19).
Categories have been developed to classify heart failure
patients based on their clinical picture. The INTERMACS
clinical profiles are used to describe various clinical pictures
and serve as a shorthand for communication for severity of
heart failure in patients that are receiving optimal medical
therapy (20).
The IMACS database provides some insights into the
number and types of devices over time. IMACS provides
yearly data regarding centrifugal vs. axial devices over time
2013–2017 with 884 vs. 2,279, 1,229 vs. 2,176, 1,339 vs.
2,405, 1,371 vs. 2,064 and 1,360 vs. 1,179 respectively. Over
this period, the drop in centrifugal pumps implanted in
2017 was likely due to the MOMENTUM-3 trial and these
patients being ineligible for inclusion in INTERMACS
dataset. Over this time-period, 16,194 LVADs have
been implanted and the proportion of patients fitting
INTERMACS profiles 1 through 7 has remained about the
same each year as shown in Table 1.
Heart transplantation continues to evolve. This evolution
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is driven, in part, by changes in the donor allocation systems
with the use of extended-criteria donor hearts [donation
after circulatory death (DCD), ex vivo perfusion supported
hearts, hepatitis C]. The expansion of the donor criteria
is because the demand for organs greatly outpaces supply.
Yearly transplant volume has increased over the last decade.
From 2010–2018, the median recipient age was 55 years,
the median donor age was 35 years, approximately 40% of
donor cause of death was head trauma, and approximately
20% was stroke. The growth of pre-transplant MCS
has been rapid from 2007 until present, but seems to be
stabilizing at the current level of approximately 50%;
LVADs make up approximately 45%, right ventricular assist
devices (RVADs) approximately 3%, total artificial hearts
(TAHs) approximately 1% and extracorporeal membranous
oxygenation (ECMOs) approximately 1% (17). Figure 2
provides additional information over time as it relates to
heart transplantation from various types of MCS. Long
term mortality is similar for transplantation from MCS,
other than ECMO as shown in Figure 3.
Availability of LVADs is functionally limitless, but heart
transplants are limited by the donor supply. Ongoing
consideration of ways to expand the donor pool is taking
place. The first reported heart transplant following
donation after circulatory death (DCD) took place in
a pediatric series in 2008 (21). The expansion of this
technique has continued as a way to expand the limited
heart donor pool. Importantly, the technique of heart
transplant following DCD has generated ethical concerns
and controversy (22,23). Most donations of organs are
after brain-stem determined death, but there are a growing
number of centers around the world including Australia,
UK, and Belgium (24). Centers that are performing heart
transplant after DCD have been having comparable short-
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Figure 2 Adult heart transplants % of patients bridged with MCS (LVAD, RVAD, TAH, ECMO) by year and device type (17). From:
International Society for Heart and Lung Transplantation. Available online: https://ishltregistries.org/downloadables/slides/2019/heart_
adult.pptx; with permission. MCS, mechanical circulatory support; LVAD, left ventricular assist device; RVAD, right ventricular assist
device; TAH, total artificial heart; ECMO, extracorporeal membrane oxygenation.

term outcomes (25).
Financial impact
The costs of heart failure on a global scale are difficult to
ascertain. There are numerous challenges to comparing
costs across countries. Challenges cited include how the
disease itself is defined, how the treatments are valued, and
where the data are sourced. A study primarily evaluating
North America, Europe, and Asia found that annual costs
ranged (in international dollars) from $868 to $25,532, with
an increase in cost noted as NYHA classification increased
(with NYHA class IV patients comprising 70% of heart
failure expenditures), increased with comorbidities (in
particular diabetes mellitus), and increased toward the end
of life. The country of residence has been significant, with
the highest costs incurred in Germany and the USA (26).
The intersection of the increasing prevalence of heart
failure with the rising cost of healthcare technology
was predicted as early as 1985 by a working group at
the National Heart, Lung, and Blood Institute who
hypothesized that the future advent of MCS would be an
expensive therapy to provide and afford (27). This prescient
prediction has sparked debates and studies over the last

© Annals of Translational Medicine. All rights reserved.

35 years as technological advances in advanced heart
failure therapies have grown. Prior to the groundbreaking
REMATCH trial, bridge to transplant (BTT) LVAD
implantation was deemed reasonable because of the
durability of eventual heart transplant survival and the
abysmal outcomes of medical management for advanced
heart failure (28). However, the dramatic mortality benefit
demonstrated in the REMATCH trial, coupled with the
rate-limiting availability of donor hearts, portended an
increased utilization of LVAD therapy for destination
therapy (DT) and a concomitant increase in related direct
and indirect healthcare costs. These predictions were born
out with the FDA approval of BTT therapy in 2008, and
DT therapy in 2010. The direct and indirect healthcare
costs of heart failure are predicted to increase dramatically
with total direct and indirect costs expected at nearly $53
billion and $17 billion, respectively, by 2030 (29).
The early studies reporting costs and cost-effectiveness
of LVADs are likely not relevant because of the significant
differences in design between first and current third
generation devices. However, these findings do provide a
reference point for cost analysis. Most early cost analyses
report daily costs or incremental costs without taking into
account efficacy. A Danish study calculated cost per life-
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International Society for Heart and Lung Transplantation. Available online: https://ishltregistries.org/downloadables/slides/2019/heart_
adult.pptx; with permission. MCS, mechanical circulatory support; LVAD, left ventricular assist device; RVAD, right ventricular assist
device; ECMO, extracorporeal membrane oxygenation.

year saved as $48,000 (30), while a study from the UK
reported the cost per quality adjusted life year (QALY) to
be $78,000 for BTT usage (31). Along the journey from
early cost analysis, evidence accrued which questioned
the cost effectiveness of second-generation devices. A
more robust analysis in the UK of the HeartMate II
for BTT demonstrated a significantly increased cost of
£258,922 ($414,275) per QALY compared to conventional
management until heart transplantation (32). The reduced
cost efficacy of the HeartMate II was presumed to be due
to the improved survival of heart transplant recipients, and
the significant acquisition costs of the device hardware.
The cost-effectiveness of the third generation HeartWare
was compared to the HeartMate II in the UK for BTT
patients which demonstrated both improved efficacy and
reduced costs of HeartWare device as demonstrated by an
incremental cost-effective ratio (ICER) of $38,697 over
the lifetime of the patient because of the improved survival
to transplantation, which incurs greater costs (33). ICER
serves as a robust cost-utility analysis to compare the costs
per QALY gained between interventions.
Although, no direct head-to-head comparison has
been performed, the cost-effectiveness of LVAD DT
has demonstrated to be less convincing in comparison
to BTT therapy. A variety of cost analyses of LVAD
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DT compared to medical management have reported
significantly increased costs per QALY. Utilizing data
obtained from the REMATCH trial, investigators reported
the ICER of $198,184 per QALY compared to medical
management, which equates to a 75% reduction in ICER,
from $802,702 per QALY, for first generation, pulsatile
flow device (34). USA Medicare data, likewise, has reported
comparable ICER of $209,400 per QALY; of which, a
significant factor is the increase in readmission rates after
LVAD implantation (35). Because of these increased costs
associated with both device implantation and readmissions,
more cost-conscious healthcare systems, such as Canada
and the UK, have resisted the expansion of DT LVAD
therapy.
Quality of life impact
Quality of life for heart failure patients is typically
measured utilizing instruments such as the Kansas City
Cardiomyopathy Questionnaire (KCCQ) or the Minnesota
Living with Heart Failure Questionnaire (MLHFQ).
These instruments utilize questions regarding activities of
daily living, shortness of breath, and edema to ascertain
the impact of heart failure on patient lives. Generally,
scores tend to improve over time, but few medical aspects
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improve the scores. Exercise and spironolactone have
demonstrated increased scores compared to control or
placebo. Ultimately, the functional limitations due to heart
failure (as classified by the New York Heart Association)
is a significant predictor of readmission and mortality (2).
Patients in Japan were scored using the Barthel index,
an instrument that assesses a patient’s ability to perform
activities of daily living. Approximately 43.4% of patient
scores worsened, which, along with low baseline scores,
correlated with being discharged to a non-home location, to
require a longer hospitalization, be readmitted, and suffer
mortality (36).
Following LVAD implantation, there is an initial
decline in quality of life indicators followed by substantial
improvement. A study utilizing the INTERMACS registry
and KCCQ survey data noted a baseline median score of
34.6 (scored 0–100, with 100 representing no impact on
quality of life) with median scores of 14.3 at 3 months,
28.1 at 6 months, 41.1 at 9 months, at 63.8 at 1 year. There
is some suggestion that there is a large improvement in
quality of life following MCS utilization. These numbers
may be biased as there was a significant association between
3-month KCCQ scores and mortality, but comparison of
mortality across score quartiles did not differ significantly
beyond this point (37).
Mortality data and trends
Considering the high mortality associated with heart
failure, patient outcomes are closely studied, particular in
Europe and North America. OPTIMIZE-HF, IMPACTHF, EFFECT, and the EuroHeart Failure Survey have
demonstrated no significant difference in mortality or
rehospitalization between patients with reduced and pEF.
OPTIMIZE-HF reported mortality rates of 37.5%, 35.1%
and 35.6% at 1 year for patients with reduced, mid-range,
and pEF in patients in the USA. EFFECT demonstrated
similar numbers for 1-year mortality for patients with
reduced and pEF (25.5% and 22.2%) in the Canadian
population. The EuroHeart Failure Survey noted an
estimated 1-year mortality rate of 23.6% for acute heart
failure and 6.4% for chronic heart failure. The Swedish
Heart Failure Registry was utilized 12 years of data to
compare mortality between patients with reduced and pEF
and found no significant difference. One-year all-cause
mortality for heart failure patients in Spain was 14%, but
found that those patients with recent hospitalization faced
an increased likelihood (24%) (38).
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In other areas of the world, data are more complete.
Thirty-day mortality rate in China is reported to be 5.3%,
while in Taiwan 3.9%. In Singapore, a 2.5% mortality rate
over 7 years was listed. A study of Korean patients reported
9.2% mortality at 1 year, and a study of patients in Japan
reported 8.9% mortality in patients with HFrEF and 11.6%
mortality in patients with HFpEF at 1 year. Numbers from
South America and Australia are more similar to those
reported in Europe and North America, with a respective
1-year mortality of 24.5% and 20.5–20.7% (10).
A multicenter European study evaluating mortality and
guideline adherence by physicians found that patients who
saw physicians who followed guideline-based practice were
93% as likely to die as those patients who did not follow
guideline-based practice over the 18-month period of the
study (39).
Data would suggest that there has been a significant
decline in mortality secondary to heart failure over the
past 50 years. A study from the USA demonstrated a 70%
decline from 206 per 100,000 in 1968 to 62 per 100,000
in 2017. This rate, however, has not significantly changed
since 2011 (40).
For patients who have undergone MCS, survival is
approximately 83% at 1 year (11). The INTERMACS
classification system, as previously mentioned, is the
most common method of describing MCS candidates.
However, more specific predictive tools have been
developed for mortality and outcomes following LVAD
implantation (37). The Destination Therapy Risk Score
was initially utilized, but was found to be poorly predictive
in continuous flow VAD patients (41). The HeartMate
II Risk Score (HRMS) was designed to predict 90-day
mortality in patients undergoing LVAD implantation and
was defined as a function of age, international normalized
ratio, albumin, creatinine, and center volume. Stratification
of INTERMACS class I patients into low, mid, and high
categories predicts a 2-year mortality of 8%, 12%, and
32%, respectively, with a c-statistic of 0.7 (42). These data
have had limited reproducibility, with minimal difference in
mortality noted between the stratified groups when applied
to other cohorts. A Bayesian model, Cardiac Outcomes
Risk Assessment (CORA), has been developed that utilizes
(I) intervention within the last 48 hours, (II) creatinine,
(III) events experienced during the hospitalization closest
to LVAD implantation, (IV) previous cardiac operations,
(V) IV inotrope therapy agent, (VI) primary diagnosis,
(VII) hemoglobin, (VIII) LVAD device strategy, and
(IX) INTERMACS profile to predict mortality with a
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c-statistic of 0.81 for 90-day mortality and 0.79 for 1 year
mortality. The most impactful events on mortality were
cardiac arrest, intubation, dialysis, extracorporeal life
support, feeding tube placement, and balloon pump
utilization (41). As machine learning becomes more
integrated into predictive modeling in the healthcare
system, there will likely be additional models to predict
heart failure associated mortality (43).
Conclusions
In summary, the increased prevalence of heart failure
has prompted increasing interest in both the medical
management and advanced therapies because of significant
effect on quality of life, mortality, and the economic burden
imposed. Continued international cooperation in registry
data collection and well-designed clinical outcomes trial
will further identify the best timing of therapies. The
tremendous growth in mechanical support for heart failure
has perhaps over-shadowed medical management. However,
the future of genomic-centered, patient-specific therapies
may balance the treatment options available to patients.
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